Open AccessInsulin for type 2 diabetes: choosing a second‐line insulin regimen
Author(s) -
Barnett A.,
Begg A.,
Dyson P.,
Feher M.,
Hamilton S.,
Munro N.
Publication year - 2008
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/j.1742-1241.2008.01909.x
Subject(s) - medicine , regimen , insulin , diabetes mellitus , type 2 diabetes , basal insulin , nph insulin , intensive care medicine , endocrinology , insulin glargine
Summary Guidance has been published on the choice of initial insulin regimen for patients with type 2 diabetes [NPH (isophane) insulin or a long‐acting insulin analogue] but not on how to choose a second regimen when glycaemic control becomes unsatisfactory. Aims: To develop pragmatic clinical guidance for choosing a second‐line insulin regimen tailored to the individual needs of patients with type 2 diabetes after failure of first‐line insulin therapy. Methods: Formulation of a consensus by expert panel based on published evidence and best clinical practice, taking into account patient preferences, lifestyle and functional capacity. Results: Six patient‐dependent factors relevant to the choice of second‐line insulin regimen and three alternative insulin regimens (twice‐daily premixed, basal‐plus and basal‐bolus) were identified. The panel recommended one or more insulin regimens compatible with each factor, emphasising the fundamental importance of a healthy lifestyle that includes exercise and weight reduction. These recommendations were incorporated into an algorithm to provide pragmatic guidance for clinicians. Conclusion: The three alternative insulin regimens offer different benefits and drawbacks and it is important to make the right choice to optimise outcomes for patients.